Citations 2
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Hodi, F. Stephen , Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Perrone, Andrea , Gammage, Linda, Hille, Darcy A., Xue, Dahai, Kang, Soonmo Peter, Chun, Patrick, Ebbinghaus, Scot, Ribas, Antoni , Daud, Adil , Robert, Caroline , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie, Wolchok, Jedd D.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3006-3006
Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).
Hamid, Omid , Hodi, F. Stephen , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Patnaik, Amita , Gergich, Kevin, Li, Xiaoyun , Chun, Patrick, Ebbinghaus, Scot, Kang, Soonmo Peter, Robert, Caroline , Ribas, Antoni , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Joseph, Richard W. , Daud, Adil
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3000-3000